European pharmaceutical cannabis product manufacturer SOMAÍ Pharmaceuticals Unipessoal LDA received authorization for its facility in Lisbon, Portugal, from the Portuguese Health Authority INFRAMED.

Why It Matters

This authorization allows the company to produce, import, and export medicinal cannabis products to numerous global markets.

It awards SOMAÍ a GMP Certificate Part I and Part II, enabling it to execute its plan to own distribution channels in Australia and Germany and to establish distribution partnerships in another eight countries while developing a comprehensive brand of medical cannabis products.

The company also announced that it has successfully raised €5 million of new capital to fund its growth plans.

How It All Started

Michael …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.